Cell Samples From Patients With Leukemia
RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about cancer and the development of drug resistance in patients. It may also help doctors find better ways to treat cancer.
PURPOSE: This research trial is studying samples from patients with leukemia.
Drug: in vitro sensitivity-directed chemotherapy
Other: cell proliferation assay
Other: fluorescence activated cell sorting
Other: laboratory biomarker analysis
|Study Design:||Observational Model: Case-Only
Time Perspective: Retrospective
|Official Title:||Xenotransplantation of Primary Leukemia Samples Into Zebrafish|
- Primary human leukemia samples capable to survive and proliferate in the zebrafish embryo
- In vivo confirmation of anti-proliferative or toxic effects of known chemotherapeutic agents on the transplanted cells
- Effects of novel anticancer drugs and/or their combinations on individual samples
Biospecimen Retention: Samples With DNA
|Study Start Date:||July 2011|
|Primary Completion Date:||May 2016 (Final data collection date for primary outcome measure)|
- Demonstrate the capability of primary human leukemia samples to survive and proliferate in the zebrafish embryo.
- Confirm the anti-proliferative or toxic effects of known chemotherapeutics on the transplanted cells in vivo.
- Evaluate the effect of novel anticancer drugs and/or their combinations on individual samples.
OUTLINE: This is a multicenter study.
Cryopreserved specimens are injected into the yolk sac of zebrafish embryos under anesthesia. After 1 hour of recovery at 28° C, embryos are maintained at 38° C and screened for fluorescence at the injection site. Within 48 hours post-injection, some embryos are treated with various chemotherapeutic drugs or dimethyl sulfoxide and incubated in protease solution. Proliferation of leukemia cells are monitored by live-cell microscopy. Cells with or without drug treatment are then extracted at 24 and 72 hours post-injection. Leukemia cells are counted and tested with imatinib mesylate, all-trans retinoic acid (tretinoin), cytosine arabinose, and known bioactive chemical compounds from promising drug families, such as tyrosine kinase inhibitors, antiapoptotic agents, channel modulators, and prostaglandin agonists.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01395628
|Principal Investigator:||Jason N. Berman, MD||IWK Health Centre|